Incidence of hematologic cancer types in Japan by ICD-O-3 code: analysis of National Cancer Registry.

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Future Science OA Pub Date : 2024-12-31 Epub Date: 2024-10-17 DOI:10.1080/20565623.2024.2413801
Ayako Muramatsu, Tetsuji Kawakami
{"title":"Incidence of hematologic cancer types in Japan by ICD-O-3 code: analysis of National Cancer Registry.","authors":"Ayako Muramatsu, Tetsuji Kawakami","doi":"10.1080/20565623.2024.2413801","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> We classified subtypes of hematologic cancer in Japan's National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology's Blood Diseases Registry (BDR).<b>Materials & methods:</b> We reviewed data for individual cases, and calculated incidence per 100,000.<b>Results:</b> NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.07 per 100,000), plasma cell myeloma (5.26/100,000), myelodysplastic syndrome, NOS (3.92/100,000), malignant lymphoma, NOS (3.03/100,000), marginal zone B-cell lymphoma, NOS (2.52/100,000) and follicular lymphoma, grade 1 (1.43/100,000). Around 48% of NCR cancers were also reported in the Blood Diseases Registry.<b>Conclusion:</b> ICD-O-3 codes revealed 12,365 additional cases to the 55,554 reported publicly. Accurately updated data are necessary for medical resource planning.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2413801"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2024.2413801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: We classified subtypes of hematologic cancer in Japan's National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology's Blood Diseases Registry (BDR).Materials & methods: We reviewed data for individual cases, and calculated incidence per 100,000.Results: NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.07 per 100,000), plasma cell myeloma (5.26/100,000), myelodysplastic syndrome, NOS (3.92/100,000), malignant lymphoma, NOS (3.03/100,000), marginal zone B-cell lymphoma, NOS (2.52/100,000) and follicular lymphoma, grade 1 (1.43/100,000). Around 48% of NCR cancers were also reported in the Blood Diseases Registry.Conclusion: ICD-O-3 codes revealed 12,365 additional cases to the 55,554 reported publicly. Accurately updated data are necessary for medical resource planning.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
按 ICD-O-3 编码划分的日本血液肿瘤类型发病率:全国癌症登记处分析。
目的:我们根据ICD-O-3代码对2016年日本国家癌症登记处(NCR)的血液肿瘤亚型进行了分类,并与日本血液学会的血液疾病登记处(BDR)的数字进行了比较:我们审查了单个病例的数据,并计算了每十万人的发病率:NCR报告了67919例血液肿瘤病例,包括弥漫大B细胞淋巴瘤、未另作说明的淋巴瘤(NOS)(11.07/100,000)、浆细胞骨髓瘤(5.26/100,000)、骨髓增生异常综合征(NOS)(3.92/100,000)、恶性淋巴瘤(NOS)(3.03/100,000)、边缘区 B 细胞淋巴瘤(NOS)(2.52/100,000)和 1 级滤泡淋巴瘤(1.43/100,000)。约 48% 的 NCR 癌症在血液病登记处也有报告:结论:ICD-O-3 编码显示,在公开报告的 55554 个病例之外,又增加了 12365 个病例。医疗资源规划需要准确更新数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future Science OA
Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
5.00
自引率
4.00%
发文量
48
审稿时长
13 weeks
期刊介绍: Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
期刊最新文献
Case report: lichen planus in a patient with ulcerative colitis receiving sulfasalazine: a drug effect or a disease manifestation? Validation of salivary proteomic biomarkers for early detection of oral cancer in the Egyptian population. Endoscope disinfectant-induced colonic pseudolipomatosis: case series of a rare condition. A comprehensive approach for detection of biotin deficiency from dried blood spot samples using liquid chromatography-mass spectrometry. Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1